First jab of modernof (NASDAQ: MRNA) The two-shot coronavirus vaccine isn’t a weapon for millions to eventually get, but the company is planning to measure the effectiveness of its supporters.
In this year’s presentation, annual J.P. Morgan The healthcare conference Moderna said it plans to do so in a clinical trial involving vaccine study participants. Previously, mRNA-1273 had begun contacting potential participants and plans to The study started in July.
“From what we’ve seen so far, I think our expectation is that vaccinations should last at least a year,” Moderna Tal Zaks Chief Medical Officer said during the meeting. “At the level where you need a booster shot, we will give you advice based on information and that will require us to be informed.”
In the planned study, Moderna will try to determine the level of immune response that continues to arise from the booster shot, CEO Stephane Bancel said at the event.
The ideal time for a follow-up study as participants in the vaccine’s first clinical trial were close to one year anniversary of booster exposure. They were first shot down in mid-March 2020.
Moderna is one of two coronavirus vaccines approved for use in an emergency by the US Food and Drug Administration. However, the release of mRNA-1273 and Pfizer/BiotechTwo BNT162b2 shots are similarly slow. The number of first-dose patients remains worrisome low.